Stock comparison
IDEXX Laboratories
Wave Life Sciences
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
WVE
Wave Life Sciences
Market cap
$1.23B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | WVE | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 31F | IDXX |
| Benjamin Graham | 80A | 55D | IDXX |
| Philip Fisher | 75B | 47D | IDXX |
| Peter Lynch | 71B | 6F | IDXX |
| Joel Greenblatt | 83C | 4F | IDXX |
| Charlie Munger | 87A | 46D | IDXX |
| Terry Smith | 84A | 45D | IDXX |
Side-by-side metrics
| Metric | IDXX | WVE |
|---|---|---|
| Market cap | $44.12B | $1.23B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | - |
| ROIC (TTM) | 40.66% | -36.32% |
| Gross margin | 62.05% | 93.79% |
| Net margin | 24.63% | -2.56% |
| Revenue CAGR 5y | 7.56% | 1.06% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs -36.32%+189%
- Net margin24.63%vs -2.56%+110%
- Market cap$44.12Bvs $1.23B+97%
- Revenue CAGR 5y7.56%vs 1.06%+86%
WVE leads on
- P/E (TTM)-vs 39.0x+120%
- EV/EBIT-vs 31.6x+112%
- Debt / Equity0.0xvs 0.7x+96%
- Gross margin93.79%vs 62.05%+34%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.